To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m 2 , n ¼ 18) or cladribine-based (0.77 mg/kg, n ¼ 2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatmentrelated mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived 4100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P ¼ 0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.
, n ¼ 18) or cladribine-based (0.77 mg/kg, n ¼ 2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatmentrelated mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived 4100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P ¼ 0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for patients with refractory hematological malignancies; however, it has been restricted to young patients without comorbidity. The introduction of reduced intensity stem cell transplantation (RIST) has expanded the treatment option to older, medically infirm patients. 1, 2 Another limitation of the treatment is the stem cell source; HLA-matched related donors are available to only 30% of the patients who require this procedure. An HLA-matched unrelated donor (MUD) is an important alternative donor source. 3 The feasibility of RIST from a MUD has not been extensively studied, leaving an optimal conditioning regimen to be determined.
As of October 2002, we had treated 191 patients with hematological diseases or solid tumors with RIST, 20 of whom underwent RIST with unrelated bone marrow (BM). This study retrospectively examined the feasibility of RIST from a MUD.
Patients and methods

Patients and donors
We studied 20 consecutive patients who underwent RIST from a MUD following either antithymocyte globulin (ATG)-or total body irradiation (TBI)-containing conditioning regimens at the Tokyo Stem Cell Transplant Consortium between January 2000 and October 2002. They were eligible for RIST due to age 450 years and/or organ dysfunction. Of the 20 patients, 17 had high-risk hematological malignancies (progressive diseases or those in 42nd remission) ( Table 1) . The other three patients were classified as having low-risk diseases. All of the patients and donors gave their written informed consent in accordance with the requirements of the Institutional Review Board.
by high-resolution DNA typing. BM was collected by a standardized technique on the day of infusion.
Preparative regimens
In the National Cancer Center Hospital, the preparative regimens used were cladribine 0.11 mg/kg on days À10 to À4 and busulfan 4 mg/kg on days À6 and À5, 6 then cladribine was replaced with fludarabine 30 mg/m 2 on days À8 to À3 as the supply of cladribine was suspended (Table 1 ). In the Toranomon Hospital, fludarabine was administered in the same schedule and cyclophosphamide was 60 mg/kg on days À3 to À2. Cyclophosphamide was switched to melphalan 140 mg/m 2 on day À1 because of the number of patients with cardiac dysfunction.
To enhance engraftment, rabbit ATG (thymoglobulin; IMTIX-SANGSTAT, Lyons, France) 2.5 mg/kg/day was administered for 2 (n ¼ 3), 2 (n ¼ 3), and 4 (n ¼ 3) consecutive days, finishing on day À1. ATG was replaced by 4 or 8 Gy fractionated TBI because of the observed high rate of graft failure. TBI was administered on day À1 in two fractions. Case 8 received ATG and total lymph node irradiation, and was classified in the ATG group in this study.
Engraftment and chimerism analysis
Engraftment was defined as a white blood cell (WBC) count of 41.0 Â 10 9 /l or an absolute neutrophil count (ANC) of 40.5 Â 10 9 /l for 2 consecutive days, and a platelet count of 420 Â 10 9 /l for 2 consecutive days without transfusions. G-CSF 300 mg/m 2 /day was administered intravenously from day 5 till neutrophil engraftment. Secondary graft failure was defined as peripheral cytopenia and marrow hypoplasia occurring later than day 21 without detection of donor markers by cytogenetic and molecular techniques.
Donor-recipient chimerism was assessed using CD3-positive cells by fluorescent in situ hybridization (FISH) in sex-mismatched donor-recipient pairs. In sex-matched pairs, multiplex amplification of short tandem repeats (STR) was used with donor cells detected at a sensitivity of 10%. 7 
Regimen-related toxicity
Regimen-related toxicity (RRT) was defined as all nonhematological organ dysfunctions from day 0 to day 28, and was graded according to the toxicity criteria developed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0 (Table 2) . Transplantrelated mortality (TRM) was nonrelapse mortality.
Supportive cares and management of GVHD
All of the patients were managed in laminar airflowequipped rooms, and received prophylaxis with trimethoprim/sulfamethoxazole or pentamidine inhalation, ciprofloxacin, fluconazole, and acyclovir. 8 Neutropenic fever was managed as described by Pizzo.
9 Cytomegalovirus (CMV) pp65 antigenemia was monitored weekly with initiation of preemptive ganciclovir at positive results. 8 GVHD prophylaxis was cyclosporin alone (n ¼ 10), or with short-term methotrexate (n ¼ 7), prednisolone 0.5 mg/ kg (n ¼ 2), or mycophenolate mofetil (n ¼ 1) (Table 1 ). In the absence of GVHD, cyclosporin was tapered from day 100 until day 180. GVHD was diagnosed based on clinical and pathological findings. Acute and chronic GVHD was graded according to the consensus criteria.
10,11
End points and statistical analysis
The primary end points were durable engraftment and TRM at day 100. The secondary end points were RRT, incidence of acute and chronic GVHD, event-free survival (EFS), and overall survival (OS). These end points were compared between ATG-and TBI-conditioned groups. EFS was defined as the post-RIST survival duration without disease progression, relapse, graft failure, or death. Probabilities of OS and EFS were calculated as a function of time by the Kaplan-Meier method. Surviving patients were censored on the last day of follow-up. A univariate analysis using Fisher's exact test and the Mann-Whitney test was performed to compare the clinical characteristics of ATG-and TBI-conditioned groups. A Cox regression analysis was used to determine the effects of several variables on OS. Significant factors were identified based on a forward stepwise procedure. The variables entered in each stepwise analysis were sex, age, disease (acute leukemia vs other, and mature B-cell neoplasms and others), risk of primary disease (high vs low), preparative regimen (TBI-containing vs ATG-containing), HLA-allele matching, time-to-RIST from diagnosis, history of autologous HSCT with high-dose chemotherapy, ABO mismatch, and the number of infused nucleated cells. P-values o0.05 were considered significant.
Results
Engraftment
The median number of nucleated cells infused was 2.6 Â 10 8 /recipients' body weight (kg) (range 0.8-5.2 Â 10 8 /kg). In all, 19 patients (95%) achieved primary neutrophil engraftment, and 12 (60%) reached more than 20 Â 10 9 /l platelets. The median time to recover an ANC of 0.5 Â 10 9 /l was 15 days (10-25), while 20.5 days (11-32) were needed to reach a platelet count above 20 Â 10 9 /l. The median number of transfused red blood cell and platelet products, within 60 days post transplant, was 12 (0-104) and 125 (10-835) units, respectively.
Graft failure
Three patients, all of whom received an ATG-containing preparative regimen, developed graft failure (primary in one and secondary in two). One patient with AML (case 4) who was refractory to conventional chemotherapy did not recover her blood cell counts, and finally died of sustained disease progression on day 48. Two patients (cases 2 and 9) developed secondary graft failure following preemptive use of ganciclovir. These patients did not respond to G-CSF therapy.
Statistical analysis showed a significant association between graft failure and the use of an ATG-containing regimen (P ¼ 0.0491). Two of the five patients who received an allele-mismatched graft developed graft failure, whereas one of the 15 patients who received a matched graft developed graft failure, and this difference was not statistically significant (P ¼ 0.071).
Chimerism analysis
Chimerism analysis was available in all but four patients who showed early disease progression (cases 4 and 20) and cytopenia (cases 1 and 2). Of these 16 patients, 15 (94%) achieved full donor T-cell chimerism by day 100. The remaining patient (case 9) had 68% donor chimerism on day 30 and subsequently developed secondary graft failure on day 38.
Toxicity
NCI-CTC grade III-IV toxicity within 28 days post transplantation was observed in seven patients (Table 2) . Five patients (25%) died of TRM within 100 days of transplant. The causes of death were pulmonary bleeding due to acute GVHD, interstitial pneumonitis, gastrointestinal bleeding, graft failure, and liver failure.
GVHD
Grade II-IV acute GVHD developed in 7/18 evaluable patients on a median of day 24 (range 19-70; Table 3 ). Three patients died of acute GVHD. Given the high risk of relapse of the underlying diseases, immunosuppressants were tapered rapidly in two patients (cases 6 and 15) to induce GVHD; case 15 died of acute GVHD and case 6 died of invasive pulmonary aspergillosis following steroid treatment for mild GVHD. Seven of the 11 patients (64%), who survived longer than 100 days, developed chronic GVHD. Chronic GVHD was preceded by acute GVHD in six patients.
Infection
Reactivation of CMV infection was documented in 8/20 (40%), while none of them developed CMV disease. One (5%) developed fungal infection, which led to TRM (Table 3) . Case 16 developed hemorrhagic cystitis attributable to adenovirus infection (serotype 11) on day 87, which responded to hydration. Table 2 Regimen-related toxicity 
Comparison of ATG-and TBI-containing regimens
These two treatment groups are compared in Table 4 . While GVHD prophylaxis tended to be more intense in the TBI group than in the ATG group, graft failure developed more frequently in the ATG group than in the TBI group (P ¼ 0.074). There was no difference in TRM between TBI and ATG groups.
Discussion
Few studies have been reported on the feasibility of RIST from a MUD. [12] [13] [14] [15] Two studies from Israeli 13 and Texas groups 12 suggest its feasibility for durable engraftment (25/ 29 vs 15/16, respectively), while the German study reported that 41/42 patients engrafted followed by 8/41 with secondary graft failure.
14 However, the variety of the conditioning regimens, GVHD prophylaxis, and patient characteristics make the risk factors for graft failure difficult to determine. The present study showed that all the 20 patients engrafted, supporting the feasibility of RIST from MUD. However, two of them developed secondary graft failure, both of whom had received ATG as part of the conditioning regimen. This may suggest a negative effect of ATG on engraftment.
ATG is comprised of polyclonal serum immunoglobulin cultivated in rabbits against T-cell lines. It has observable effects on T cells for up to 4 days after administration. 16 Thus, ATG can deplete both host-and donor-derived T cells and inhibits GVHD due to its long half-life. 17 In contrast, TBI has no effect on donor-derived T cells. These findings support the contention that the use of ATG in RIST from MUD is associated with a high rate of graft failure, while TBI-containing regimens might enhance engraftment. Since we replaced ATG with TBI, we have not experienced any graft failure. This is consistent with a previous report that TBI-containing RIST from MUD has attained engraftment in patients with aplastic anemia. 18 However, it is to be noted that our purine analog-based regimens using intermediate-dose TBI cause considerable myelosuppression. Since regimen-related toxicities were moderate and acceptable in this study, we consider that our regimens are classified as reduced intensity regimens. Further investigation is warranted to investigate optimal preparative regimens for RIST. Another method to enhance engraftment is use of peripheral blood stem cell (PBSC) transplantation instead of BM. 15 Since PBSC collections contain more CD34-positive and T cells than BM, they may be advantageous in achieving engraftment in RIST from MUD.
GVHD is the most important problem in RIST. In the present study, there were more patients with grade II-IV GVHD in the TBI group (n ¼ 5) than in the ATG group (n ¼ 2) despite additional GVHD prophylaxis with MTX. This may be because ATG reduces the frequency and severity of GVHD by suppressing T cells in the graft. However, day 100 TRM tended to be lower in the TBI group (n ¼ 1) than in the ATG group (n ¼ 4). These results suggest that TBI-containing regimens are safer in RIST from MUD than ATG-containing regimens; however, further studies are required to improve management of GVHD following RIST from MUD.
The incidences of CMV reactivation and disease have been reported to be higher in conventional SCT from MUD (87 and 73%) than conventional SCT from matched siblings (53 and 14%). 19 HSCT from unrelated donors achieves immune reconstitution later than HSCT from related donors, which leads to a higher risk for severe infections. 19 Our study revealed that the incidences of fungal infection and CMV reactivation were, respectively, 15 and 54%, which are comparable to the reports in conventional SCT recipients. 20, 21 Our results suggest that RIST with BM from MUD is feasible. However, we should comment on some limitations of this study. First, patients who had been enrolled on some pilot studies of RIST were analyzed in this study, and several different preparative regimens and GVHD prophylaxis were utilized. Second, the two comparison groups (ATG vs TBI) had different follow-up periods. This might complicate the interpretation of OS and EFS data when one attempts to compare the two groups. While this study suggests that RIST from MUD is feasible, further studies are required to improve its safety and efficacy. The use of intermediate-dose TBI as an alternative to ATG may enhance engraftment, although the optimal dose of TBI and GVHD prophylaxis regimen remains to be defined. 
